Sonoma Pharmaceuticals Inc

Effective February 7, 2024, our Board of Directors appointed Jerome Dvonch as our Chief Financial Officer. Prior to this appointment, Mr. Dvonch has served as our interim Chief Financial Officer since April 7, 2023.

Mr. Dvonch will be employed at-will on a full-time basis. We agreed to compensate Mr. Dvonch $240,000 per year. Mr. Dvonch is eligible for a bonus up to 50% of his annual salary, prorated the first year based on a fiscal year end of March 31 and dependent upon meeting specified performance goals. He is also eligible for equity grants within the normal employee equity programs and for benefits, such as vacation, and our medical, dental, vision and retirement plans.

The foregoing description is not complete and is qualified in its entirety by reference to the full text of the offer letter to Mr. Dvonch, a copy of which is filed herewith as Exhibit 10.41 to this Quarterly Report on Form 10-Q and incorporated herein by reference.

Also on February 7, 2024, we entered into a new offer letter with our Controller, John Dal Poggetto, pursuant to which Mr. Dal Poggetto will be employed at-will on a full-time basis. We agreed to compensate Mr. Dal Poggetto $200,000 per year. Mr. Dal Poggetto is eligible for a bonus up to 20% of his annual salary, prorated the first year based on a fiscal year end of March 31 and dependent upon meeting specified performance goals. He is also eligible for equity grants within the normal employee equity programs and for benefits, such as vacation, and our medical, dental, vision and retirement plans.

The foregoing description is not complete and is qualified in its entirety by reference to the full text of the offer letter to Mr. Dal Poggetto, a copy of which is filed herewith as Exhibit 10.42 to this Quarterly Report on Form 10-Q and incorporated herein by reference.